Physician profile
Robert W Horowitz
NPI 1578667960
$15,109.19
in general payments reported to CMS, 2019-2025
81 companies · $3,646 in 2025
The $3,646 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $1,977 · 2021: $2,687 · 2022: $1,491 · 2023: $1,599 · 2024: $2,095 · 2025: $3,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790 · Consulting Fee: $2,153 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,789.51 |
| Consulting Fee | $2,153.00 |
| Education | $397.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,142.42 | 2019-2025 | Tagrisso, Calquence, Lynparza |
| Gilead Sciences, INC. | $1,161.95 | 2021-2025 | Trodelvy |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Janssen Biotech, INC. | $865.03 | 2019-2025 | Rybrevant, Erleada, Carvykti |
| Daiichi Sankyo INC. | $792.14 | 2019-2025 | Datroway, Enhertu |
| Eisai INC. | $736.86 | 2019-2025 | |
| Emd Serono, INC. | $635.26 | 2019-2025 | Bavencio |
| Beigene, Ltd. | $525.00 | 2021 | |
| Lilly USA, LLC | $423.76 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Novartis Pharmaceuticals Corporation | $422.57 | 2019-2025 | |
| Cipla USA INC. | $405.00 | 2025 | |
| Halozyme INC | $373.00 | 2024 | |
| Array Biopharma INC | $306.64 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $266.88 | 2019-2025 | Jakafi |
| Novocure Gmbh | $250.00 | 2022 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.